Katherine Li

Katherine Li has a diverse work experience in the fields of business development, strategy, and consulting. Katherine is currently working as the Senior Director of Business Development and Strategy at Alpha-9 Theranostics Inc. since December 2022. Before that, they held the position of Director of Business Development and Strategy at the same company from September 2021 to December 2022. Katherine also worked as a Consultant at Flagship Pioneering from November 2020 to February 2021.

In 2020, Katherine worked as a Consultant at Cerevel Therapeutics, where they were involved in product and commercial planning for CNS pipeline, including leading a market testing project for a lead asset in Parkinson's disease.

From 2017 to 2019, Katherine worked at Pfizer, first as a Manager of Business Development, where they executed various business development transactions, and later as a Senior Manager of Business Development. Katherine was involved in partnerships, licensing, M&A, and divestitures across multiple therapeutic areas, including closing deals such as the Joint Venture with GSK Consumer Health and the divestiture of Pfizer's ADHD portfolio and Epipen manufacturing business.

Prior to Pfizer, Katherine worked as a Private Equity Associate at Court Square Capital Partners from 2015 to 2017, where they led due diligence and deal execution for healthcare acquisitions totaling approximately $200M in deployed capital. Katherine worked on the acquisition of a medical-surgical supplies distributor and a wheelchair provider.

Katherine started their career as an Investment Banking Analyst at Credit Suisse from June 2013 to August 2015.

Overall, Katherine Li has demonstrated expertise in business development, strategy, consulting, and private equity, with a focus on the healthcare industry.

Katherine Li's educational background includes a Bachelor of Arts degree in Biology, which was obtained from the University of Pennsylvania from 2009 to 2013. During the same period, they attended The Wharton School and earned a Bachelor of Science in Finance. Later, in 2019 to 2021, they pursued a Master of Business Administration (MBA) degree at the MIT Sloan School of Management.